Signaling-specific inhibition of the CB1receptor for cannabis use disorder: phase 1 and phase 2a randomized trials

MLA

Haney, Margaret, et al. “Signaling-Specific Inhibition of the CB1receptor for Cannabis Use Disorder: Phase 1 and Phase 2a Randomized Trials.” Nature Medicine, no. Preprints, Jan. 2023, pp. 1–13. EBSCOhost, https://doi.org/10.1038/s41591-023-02381-w.

APA

Haney, M., Vallée, M., Fabre, S., Collins Reed, S., Zanese, M., Campistron, G., Arout, C. A., Foltin, R. W., Cooper, Z. D., Kearney-Ramos, T., Metna, M., Justinova, Z., Schindler, C., Hebert-Chatelain, E., Bellocchio, L., Cathala, A., Bari, A., Serrat, R., Finlay, D. B., … Piazza, P. V. (2023). Signaling-specific inhibition of the CB1receptor for cannabis use disorder: phase 1 and phase 2a randomized trials. Nature Medicine, Preprints, 1–13. https://doi.org/10.1038/s41591-023-02381-w

Chicago

Haney, Margaret, Monique Vallée, Sandy Fabre, Stephanie Collins Reed, Marion Zanese, Ghislaine Campistron, Caroline A. Arout, et al. 2023. “Signaling-Specific Inhibition of the CB1receptor for Cannabis Use Disorder: Phase 1 and Phase 2a Randomized Trials.” Nature Medicine, no. Preprints (January): 1–13. doi:10.1038/s41591-023-02381-w.